DE2050477A1 - Mittel zur Erzeugung einer Lysosome Labilität sowie Verfahren zur Herstellung desselben - Google Patents
Mittel zur Erzeugung einer Lysosome Labilität sowie Verfahren zur Herstellung desselbenInfo
- Publication number
- DE2050477A1 DE2050477A1 DE19702050477 DE2050477A DE2050477A1 DE 2050477 A1 DE2050477 A1 DE 2050477A1 DE 19702050477 DE19702050477 DE 19702050477 DE 2050477 A DE2050477 A DE 2050477A DE 2050477 A1 DE2050477 A1 DE 2050477A1
- Authority
- DE
- Germany
- Prior art keywords
- producing
- lipoprotein lipase
- cancer
- lysosome
- mucor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 13
- 210000003712 lysosome Anatomy 0.000 title claims description 12
- 230000001868 lysosomic effect Effects 0.000 title claims description 12
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 27
- 102000043296 Lipoprotein lipases Human genes 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 241000235395 Mucor Species 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000012876 carrier material Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000002523 gelfiltration Methods 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 7
- 229920005654 Sephadex Polymers 0.000 description 6
- 239000012507 Sephadex™ Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100022119 Lipoprotein lipase Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 241000498617 Mucor javanicus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000009916 Yoshida Sarcoma Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 108010002712 deoxyribonuclease II Proteins 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- CBMFIOOVRYZOBT-DAWNIORJSA-N mitomycin k Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1C(=C)[C@]1(OC)N2C[C@H]2[C@@H]1N2C CBMFIOOVRYZOBT-DAWNIORJSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- -1 polyoxyethylene monostearate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01034—Lipoprotein lipase (3.1.1.34)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8213269 | 1969-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2050477A1 true DE2050477A1 (de) | 1971-04-22 |
Family
ID=13765871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19702050477 Pending DE2050477A1 (de) | 1969-10-14 | 1970-10-14 | Mittel zur Erzeugung einer Lysosome Labilität sowie Verfahren zur Herstellung desselben |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE2050477A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2070125B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1332663A (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5017559B2 (enrdf_load_stackoverflow) * | 1972-09-20 | 1975-06-21 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1440497A (fr) * | 1964-07-18 | 1966-05-27 | Amano Pharma Co Ltd | Procédé de préparation d'une lipase lipoprotéinique par culture de germes |
-
1970
- 1970-10-05 GB GB4723070A patent/GB1332663A/en not_active Expired
- 1970-10-09 FR FR7036514A patent/FR2070125B1/fr not_active Expired
- 1970-10-14 DE DE19702050477 patent/DE2050477A1/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR2070125A1 (enrdf_load_stackoverflow) | 1971-09-10 |
| FR2070125B1 (enrdf_load_stackoverflow) | 1975-06-06 |
| GB1332663A (en) | 1973-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3102621C2 (enrdf_load_stackoverflow) | ||
| DE4134854C2 (enrdf_load_stackoverflow) | ||
| DE2731570C3 (de) | Verfahren zur Gewinnung eines Polysaccharide mit therapeutischer Wirkung | |
| EP0225496A2 (de) | Immunstimulierend wirkende Polysaccharide aus Zellkulturen von Echinacea purpurea (Linné) Moench und Echinacea angustifolia (De Vandolle), Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen | |
| DE3689493T2 (de) | Verfahren zur Herstellung von reinem natürlichen Heparansulfat und Dermatansulfat und ihre pharmazeutische Verwendung. | |
| CH664897A5 (de) | Gereinigtes, entgiftetes endotoxin enthaltende pharmazeutische zusammensetzung. | |
| DE2441454A1 (de) | Verfahren zur herstellung eines heilmittels fuer leukaemie | |
| DE3782430T2 (de) | Verwendung eines trypsininhibitors des kunitztyps aus sojabohnen und seiner derivate zur herstellung von medikamenten und denselben enthaltendes agens. | |
| DE2006446C3 (de) | Verfahren zur Herstellung von Bleomycin-Antibiotika sowie Bleomycine mit strukturell abgewandelter Seitenkette | |
| DE2723451C2 (enrdf_load_stackoverflow) | ||
| DE2050477A1 (de) | Mittel zur Erzeugung einer Lysosome Labilität sowie Verfahren zur Herstellung desselben | |
| DE2605576C3 (de) | Verfahren zum Isolieren der Proteasen Papain,,Chimopapain, Lysozym und Proteinase X aus dem Milchsaft von Carica papya und Verwendung der isolierten Proteasen zur Herstellung von sterilisierten und Iyophilisirten orthopädischen, neurochirurgischen oder ophthalmologischen Präparaten | |
| DE3019895C2 (enrdf_load_stackoverflow) | ||
| DE1642676A1 (de) | Verfahren zur Reinigung von Lipopolysacchariden | |
| DE3879220T2 (de) | Verminderung des gehaltes an lipoproteine mit geringer dichte in biologischen flüssigkeiten. | |
| DE3784768T2 (de) | Verwendung von zusammensetzungen auf basis von crotoxin, zur herstellung von medikamenten zur behandlung von carcinomen. | |
| CH639133A5 (de) | Verfahren zur herstellung einer antitumor wirksamen substanz mit immunostimulierender wirkung. | |
| DD222895A5 (de) | Verfahren zur herstellung eines hypotriglyceridemisch aktiven polysaccharids | |
| DE2428955C3 (de) | Verfahren zur Abtrennung der enzymatischen Komponente mit in vivo antikoagulierender und in vitro koagulierender Wirkung aus dem Gift der Schlange Ancistrodon rhodostoma und daraus hergestellte Mittel | |
| DE2528460A1 (de) | Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans | |
| DE2145528C3 (de) | Exonuclease und diese enthaltendes cytostatisches Mittel | |
| DE3329255C2 (de) | Verfahren zur Herstellung der Substanz TF-500 mit carcinostatischen und immunostimulierenden Eigenschaften | |
| DE1115888B (de) | Verfahren zur Herstellung eines Streptokinase-Praeparates | |
| DE2146674C3 (de) | Faktor und seine Verwendung als Arzneimittel | |
| DE3323093C2 (de) | Pharmazeutisches Präparat zur Bekämpfung von Tumoren |